Liraglutide as Additional Treatment in Type 1 Diabetes

Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri and Paresh Dandona

Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo
"J.L." before insulin on December 7, 1922 (15 pounds) and after insulin on February 26, 1923 (30 pounds).
The Incretin Effect
Beta-Cell Response to Oral vs IV Glucose

Crossover of Healthy Subjects (n = 6)
- Oral Glucose
- Intravenous (IV) Glucose

Plasma Glucose (mg/dL)

C-peptide (nmol/L)

Mean (SE); *P<0.05
Data from Nauck MA, et al. J Clin Endocrinol Metab. 1986;63:492-498
VICTOZA®
liraglutide (rDNA origin) injection
Standard Deviation decreased average of 20 mg/dl!
1) DF
Pre-Victoza
HBA1C = 7.4

On Victoza

Post Victoza
The Pathogenesis of Type 2 Diabetes
Beta-Cell Workload Outpaces Beta-Cell Response

Healthy Subjects (n = 14)
Type 2 Diabetes (n = 12)

Carbohydrate Meal

- Insulin (μU/mL)
- Glucagon (pg/mL)
- Glucose (mg/dL)

Mean (SE)

3) KG Pre Vitoza A1C 6.5

On Vitoza